- Trials with a EudraCT protocol (30)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
30 result(s) found for: Drug carriers.
Displaying page 1 of 2.
EudraCT Number: 2018-003954-26 | Sponsor Protocol Number: STAR22 | Start Date*: 2019-01-30 |
Sponsor Name:Erasmus MC Cancer Institute | ||
Full Title: CYP3A4*22 genotype-guided dosing of TKIs in cancer patients: a new way of personalized therapy | ||
Medical condition: Patients diagnosed with a neoplasm and treated with a tyrosine kinase inhibitor which is mainly metabolised by CYP3A4. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2006-002348-27 | Sponsor Protocol Number: PH2/052 | Start Date*: 2007-10-26 |
Sponsor Name:Cancer Research UK | ||
Full Title: A Cancer Research UK Phase II Proof of Principle Trial of the activity of the PARP-1 inhibitor, AG-014699, in known carriers of a BRCA 1 or BRCA 2 mutation with locally advanced or metastatic breas... | ||
Medical condition: advanced or metastatic breast or ovarian carcinoma (proven carrier of a mutation in BRCA1 or 2 gene) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2015-001888-39 | Sponsor Protocol Number: PGX-HT | Start Date*: 2016-01-28 | |||||||||||
Sponsor Name:OSPEDALE SAN RAFFAELE | |||||||||||||
Full Title: PHARMACOGENOMICS HYPERTENSION : A NEW APPROACH FOR PERSONALIZED MEDICINE ( PGX - HT ) | |||||||||||||
Medical condition: Hypertension | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-005667-34 | Sponsor Protocol Number: G0701625 | Start Date*: 2009-01-16 | |||||||||||
Sponsor Name:University of Edinburgh [...] | |||||||||||||
Full Title: Randomised Trial of Genetic Testing and Targeted Zoledronic acid therapy to Prevent SQSTM1 Mediated Paget's Disease (Zoledronate in the Prevention of Paget's). | |||||||||||||
Medical condition: Paget's disease of the bone (PDB) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) IT (Completed) IE (Completed) ES (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-004402-10 | Sponsor Protocol Number: APHP180587 | Start Date*: 2020-03-11 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: Fecal transplantation to Eradicate Colonizing Emergent Superbugs | |||||||||||||
Medical condition: Patients colonized with MDR-GNB (multi-drug resistant Gram Negative bacteria ) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-003034-16 | Sponsor Protocol Number: FNOL-IVA-ICD | Start Date*: 2014-05-12 |
Sponsor Name:University Hospital Olomouc | ||
Full Title: Antiarrhythmic and antiremodelation effects of ivabradin in ICD carriers | ||
Medical condition: Heart failure | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2016-004576-22 | Sponsor Protocol Number: IRI28 | Start Date*: 2017-07-14 |
Sponsor Name:Catharina Hospital Eindhoven | ||
Full Title: SAFETY, FEASIBILITY AND COST-ANALYSIS OF UGT1A1 GENOTYPE-GUIDED DOSING OF IRINOTECAN | ||
Medical condition: Cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-003807-32 | Sponsor Protocol Number: BT200-02 | Start Date*: 2020-12-16 |
Sponsor Name:Medical University of Vienna | ||
Full Title: A Phase 2a Multiple Dose “Basket Design” Study Of The Safety, Tolerability, And Pharmacologic Activity Of BT200 In Patients With Hereditary Bleeding Disorders | ||
Medical condition: - Patients with severe congenital hemophilia A - Patients with mild-moderate hemophilia A - Heterozygous carriers of hemophilia A - Patients with VWD Type 1, e.g. “Vicenza” type - Acquired Von Will... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-000138-20 | Sponsor Protocol Number: AL001-2 | Start Date*: 2019-11-18 | |||||||||||
Sponsor Name:Alector Inc. | |||||||||||||
Full Title: A Phase 2, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AL001 in Heterozygous Carriers of Granulin or C9ORF72 Mutations Causative of... | |||||||||||||
Medical condition: Frontotemporal Dementia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) NL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-003568-20 | Sponsor Protocol Number: RGR | Start Date*: 2008-08-08 |
Sponsor Name:Prof Alice Stanton | ||
Full Title: Renin Genotype and Response to Renin Angiotensin System Blockade. | ||
Medical condition: Hypertension | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IE (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-005308-12 | Sponsor Protocol Number: 1111 | Start Date*: 2018-09-07 | |||||||||||
Sponsor Name:Region Sjælland, Slagelse Hospital | |||||||||||||
Full Title: Treatment of MRSA throat carriage with mupirocin irrigation | |||||||||||||
Medical condition: Patientents being MRSA positive for a minimum of 6 months and concluded at least one konventional topical treatments unsuccessfully | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-005995-14 | Sponsor Protocol Number: 3133K1-3001-WW(B2521002) | Start Date*: 2009-05-29 | |||||||||||
Sponsor Name:Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc, 500 Arcola road, Collegeville, PA 19426 USA | |||||||||||||
Full Title: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Mild to Moderate Alzheimer Disea... | |||||||||||||
Medical condition: Alzheimer Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) IE (Prematurely Ended) BE (Prematurely Ended) DE (Prematurely Ended) FR (Completed) FI (Prematurely Ended) SE (Prematurely Ended) IT (Prematurely Ended) PT (Prematurely Ended) AT (Prematurely Ended) NL (Prematurely Ended) DK (Prematurely Ended) ES (Prematurely Ended) SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-005994-79 | Sponsor Protocol Number: 3133K1-3000-WW | Start Date*: 2008-05-13 | |||||||||||
Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development | |||||||||||||
Full Title: Ensayo de fase III, multicéntrico, aleatorizado, en doble ciego, controlado con placebo y de grupos paralelos, sobre la eficacia y la seguridad del bapineuzumab (AAB-001, ELN115727) en pacientes co... | |||||||||||||
Medical condition: Enfermedad de Alzheimer Alzheimer Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) IE (Prematurely Ended) GB (Prematurely Ended) BE (Completed) DE (Prematurely Ended) FR (Completed) FI (Prematurely Ended) SE (Prematurely Ended) IT (Prematurely Ended) SK (Completed) PT (Prematurely Ended) AT (Prematurely Ended) NL (Prematurely Ended) DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001014-37 | Sponsor Protocol Number: ALTUM | Start Date*: 2020-08-13 | ||||||||||||||||
Sponsor Name:OSPEDALE SAN RAFFAELE | ||||||||||||||||||
Full Title: Pharmacogenetics of hypertension: randomized monocentric study in patients with essential hypertension and treated with Spironolactone or Torasemide | ||||||||||||||||||
Medical condition: Essential hypertension | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002949-42 | Sponsor Protocol Number: PACT-29 | Start Date*: 2020-11-27 | |||||||||||
Sponsor Name:OSPEDALE SAN RAFFAELE | |||||||||||||
Full Title: A pilot study of chlorambucil in pre-treated metastatic pancreatic adenocarcinoma patients bearing a germ line BRCA or other DNA Defects Repair (DDR) mutations. | |||||||||||||
Medical condition: Patients affected by metastatic pancreatic adenocarcinoma (PDAC). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003888-22 | Sponsor Protocol Number: MEF-HF-2020-01 | Start Date*: 2020-11-17 |
Sponsor Name:University of Zagreb School of Medicine | ||
Full Title: A multicENter, randomized, open-label, parallel group, pilot study to evaluate the use of sacubitril/valsartan in HeartMate 3 LVAD recipients | ||
Medical condition: Heart failure Heart failure with reduced ejection fraction Advanced Heart failure | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: HR (Ongoing) NL (Completed) PL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2013-000307-17 | Sponsor Protocol Number: DIAN-TU-001 | Start Date*: 2014-01-08 |
Sponsor Name:Washington University in St. Louis | ||
Full Title: A Phase II/III randomized, double-blind, placebo-controlled, cognitive endpoint, multicenter study of potential disease modifying therapies in individuals at risk for and with dominantly inherited ... | ||
Medical condition: Dominantly Inherited Alzheimer Disease (DIAD) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) IT (Trial now transitioned) ES (Temporarily Halted) DE (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2020-000986-17 | Sponsor Protocol Number: ALZ-801-201ADBM | Start Date*: 2020-09-11 |
Sponsor Name:Alzheon Inc. | ||
Full Title: A Phase 2, Single Arm, Study of the Biomarker Effects of ALZ-801 in Subjects with Early Alzheimer’s Disease Who Are Carriers of the ε4 Variant of the Apolipoprotein E Gene (APOE4/4 or APOE3/4) | ||
Medical condition: Subjects with a clinical diagnosis of Alzheimer's disease who are APOE 4 carriers (APOE4/4, APOE3/4) and at the Early stage of disease, ages 50-80 years | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Trial now transitioned) NL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2018-001344-57 | Sponsor Protocol Number: PENTALLO | Start Date*: 2019-10-10 | |||||||||||
Sponsor Name:GITMO GRUPPO ITALIANO PER IL TRAPIANTO DI MIDOLLO OSSEO, CELLULE STAMINALI EMOPOIETICHE E TERAPIA | |||||||||||||
Full Title: Pentaglobin as early adjuvant treatment for febrile neutropenia in acute leukemia or allogeneic hematopoietic stem cell transplant patients colonized by carbapenem-resistant Enterobacteriaceae or P... | |||||||||||||
Medical condition: The study will enroll consecutive adult patients suffering from acute leukemia candidate to intensive chemotherapy or patients with hematological cancers candidate to allogeneic transplant with a d... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-012748-17 | Sponsor Protocol Number: ELN115727-301 | Start Date*: 2010-03-11 | |||||||||||
Sponsor Name:Janssen Alzheimer Immunotherapy | |||||||||||||
Full Title: A phase 3, multicenter, randomised, double-blind, placebo-controlled, parallel group, efficacy and safety trial of bapineuzumab (AAB-001, ELN115727) in subjects with mild to moderate Alzheimer's di... | |||||||||||||
Medical condition: Alzheimer's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
